Myasthenia Gravis: Treating the Whole Patient
Nicholas J. Silvestri, MD, Associate Professor, Department of Neurology, University at Buffalo Jacobs School of Medicine & Biomedical Sciences; Staff Physician, UBMD, Buffalo, New York
Nicholas J. Silvestri, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Argenx; Alexion; Immunovant; UCB
Serve(d) as a speaker or a member of a speakers bureau for: Argenx; Alexion; UCB
In the dynamic field of myasthenia gravis (MG) treatment, characterized by recent therapeutic advancements and a promising pipeline, Nicholas J. Silvestri, MD, advises early-career professionals to approach the whole patient, considering not only the disease manifestations but also its broader impact on their lives, including work and family.
Emphasizing the importance of tailoring therapies based on individual needs, Dr Silvestri encourages early and aggressive intervention, citing evidence supporting better long-term outcomes, and underscores the significance of treating the whole patient rather than just the disease.
,false